查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1791567

全球克隆與誘變市場

Cloning and Mutagenesis
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 178 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球克隆和誘變市場規模將達到 103 億美元

全球克隆和誘變市場規模預計在2024年為34億美元，預計到2030年將達到103億美元，2024年至2030年的複合年成長率為20.0%。克隆試劑套件是本報告分析的細分市場之一，預計其複合年成長率為23.2%，到分析期結束時規模將達到51億美元。誘變試劑套件細分市場在分析期間的複合年成長率預計為19.1%。

美國市場規模估計為 9.65 億美元，中國市場預計複合年成長率為 18.7%

預計到2024年，美國克隆和誘變市場規模將達到9.065億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到16億美元，在2024-2030年的分析期間內，複合年成長率為18.7%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為18.8%和16.9%。在歐洲，預計德國市場的複合年成長率約為14.3%。

全球克隆和誘變市場—主要趨勢和促進因素摘要

是什麼推動了克隆和誘變需求的激增？

克隆和誘變已成為生物技術、製藥和農業科學等各個領域的重要組成部分。對基因改造生物 (GMO) 和生物製藥的日益成長的需求是該市場的主要驅動力。在醫療保健領域，基因治療的進步推動了對克隆技術的需求，尤其是在再生醫學和精準腫瘤學領域。此外，高通量誘變技術的發展大大加速了基因工程研究，使得能夠創建功能增強的修飾蛋白質。癌症、糖尿病和遺傳疾病等慢性疾病的增加加劇了分子生物學研究，進一步刺激了對克隆和誘變工具的投資。此外，操縱遺傳物質用於藥物發現和疫苗開發的能力正在增加市場的吸引力，尤其是隨著 mRNA 技術的進步。製藥公司正在利用這些技術生產更有效的治療性蛋白質、抗體和基因編輯解決方案，從而在全球範圍內廣泛應用。

科技如何重塑複製和誘變的未來？

CRISPR-Cas9 和其他基因編輯技術的進步徹底改變了克隆和誘變的模式。次世代定序儀(NGS) 的引入使得精準基因修飾成為可能，並顯著減少了傳統上與這些技術相關的時間和成本限制。自動化和人工智慧主導的工作流程使實驗室能夠更有效率地進行高通量誘變實驗，縮短了研究和產品開發的周轉時間。此外，合成生物學與克隆和誘變技術的融合促進了新型生物合成途徑的創建，從而拓展了這些技術的應用範圍。定向進化方法的出現，利用誘變技術人工增強蛋白質功能，在酵素工程和工業生物技術領域獲得了廣泛關注。研究人員也致力於改進特異性誘變技術，以實現更精確的基因修飾，最大限度地減少脫靶效應，並提高實驗結果的可靠性。

影響競爭格局的主要市場趨勢有哪些？

市場競爭日益激烈，各公司都在大力投資研發以獲得技術優勢。推動市場擴張的關鍵趨勢是提供克隆和誘變專業服務的合約研究組織（CRO）的興起。這種轉變在製藥和生技公司中尤其明顯，它們將研究外包以降低新藥的成本和上市縮短時間。另一個新興趨勢是採用雲端基礎的生物資訊平台。這些平台使研究人員能夠遠端設計和分析誘變實驗，促進協作並提高數據準確性。此外，開放獲取基因資料庫的激增使科學家能夠利用龐大的基因資訊庫進行更明智的克隆實驗。隨著相關人員尋求開發更個人化的治療性介入，預計對合成生物學和精準醫療的資金增加將刺激進一步的技術創新。

推動市場擴張的成長要素有哪些？

克隆和誘變市場的成長受到多種因素的推動，包括對基因組研究的投入增加、在藥物發現中的應用不斷擴展以及合成生物學作用的不斷擴大。疫情過後，製藥業對誘變技術在抗體開發和疫苗研究中的依賴加劇，導致基因工程工具的採用率上升。此外，農業生物技術的進步，例如培育出抗病蟲害和惡劣環境條件的基因改造作物，正在推動對克隆技術的需求。對更高效生產重組蛋白和生質燃料的需求也推動了工業生物技術中先進誘變技術的應用。此外，監管支持和政府對基因組編輯計劃的資助進一步推動了市場擴張，使複製和誘變成為未來科技創新的重要支柱。

部分

產品類型（克隆試劑套件、誘變試劑套件、其他產品類型）、技術（拓撲 PCR 克隆技術、定點突變技術、平端克隆技術、無縫克隆技術、其他技術）、最終用戶（生物製藥/製藥公司、CRO/CMO、學術/研究機構）

受訪公司範例

  • Agilent Technologies, Inc.
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • Bolder BioTechnology, Inc.
  • Creative Biogene
  • Danaher Corporation
  • Genes2Me
  • Genewiz（Azenta Life Sciences）
  • Genomax Technologies Pte Ltd
  • GenScript
  • Integrated DNA Technologies（IDT）
  • Jena Bioscience GmbH
  • Merck KGaA
  • New England Biolabs
  • OriGene Technologies
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TransGen Biotech Co., Ltd.
  • Vazyme

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP29999

Global Cloning and Mutagenesis Market to Reach US$10.3 Billion by 2030

The global market for Cloning and Mutagenesis estimated at US$3.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Cloning Kits, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Mutagenesis Kits segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$906.5 Million While China is Forecast to Grow at 18.7% CAGR

The Cloning and Mutagenesis market in the U.S. is estimated at US$906.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.8% and 16.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Cloning and Mutagenesis Market - Key Trends & Drivers Summarized

What Is Driving the Surging Demand for Cloning and Mutagenesis?

Cloning and mutagenesis have become integral components in various fields such as biotechnology, pharmaceuticals, and agricultural sciences. The increasing demand for genetically modified organisms (GMOs) and biopharmaceuticals is a crucial driver of this market. In the healthcare sector, gene therapy advancements have propelled the demand for cloning technologies, particularly for regenerative medicine and precision oncology. Furthermore, the development of high-throughput mutagenesis techniques has significantly accelerated research in genetic engineering, enabling the creation of modified proteins with enhanced functionalities. The rising prevalence of chronic diseases such as cancer, diabetes, and genetic disorders has intensified research efforts in molecular biology, further fueling investments in cloning and mutagenesis tools. Additionally, the ability to manipulate genetic material for drug discovery and vaccine development is enhancing the market’s attractiveness, particularly with the ongoing exploration of mRNA technology. Pharmaceutical companies are leveraging these technologies to produce more effective therapeutic proteins, antibodies, and gene-editing solutions, which are seeing increased adoption worldwide.

How Is Technology Reshaping the Future of Cloning and Mutagenesis?

Advancements in CRISPR-Cas9 and other gene-editing technologies have revolutionized the cloning and mutagenesis landscape. The introduction of next-generation sequencing (NGS) has enabled precise genetic modifications, drastically reducing time and cost constraints traditionally associated with these techniques. With automation and AI-driven workflows, laboratories are now able to execute high-throughput mutagenesis experiments with greater efficiency, ensuring faster turnaround times for research and product development. Moreover, the convergence of synthetic biology with cloning and mutagenesis is facilitating the creation of novel biosynthetic pathways, thereby expanding the application scope of these technologies. The emergence of directed evolution approaches, where mutagenesis is used to artificially enhance protein functions, has gained traction in enzyme engineering and industrial biotechnology. Researchers are also focusing on improving site-directed mutagenesis techniques to enable more precise genetic alterations, minimizing off-target effects and increasing reliability in experimental outcomes.

What Are the Key Market Trends That Are Shaping the Competitive Landscape?

The market landscape for cloning and mutagenesis is increasingly competitive, with companies investing heavily in research and development to gain a technological edge. A significant trend driving market expansion is the rise of contract research organizations (CROs) that provide specialized cloning and mutagenesis services. This shift is particularly notable in pharmaceutical and biotech firms, which are outsourcing research to reduce costs and accelerate time-to-market for new drugs. Another emerging trend is the adoption of cloud-based bioinformatics platforms that allow researchers to design and analyze mutagenesis experiments remotely, facilitating collaboration and improving data accuracy. Additionally, the proliferation of open-access genetic databases is enabling scientists to leverage vast genetic information repositories for more informed cloning experiments. The increasing funding for synthetic biology and precision medicine is expected to spur further innovations, as stakeholders seek to develop more personalized therapeutic interventions.

What Are the Growth Drivers Fueling Market Expansion?

The growth in the cloning and mutagenesis market is driven by several factors, including rising investments in genomic research, increasing applications in drug discovery, and the expanding role of synthetic biology. The pharmaceutical industry’s reliance on mutagenesis for antibody development and vaccine research has intensified post-pandemic, leading to higher adoption rates of genetic engineering tools. Moreover, advancements in agriculture biotechnology, such as the creation of genetically modified crops resistant to pests and harsh environmental conditions, are propelling the demand for cloning technologies. The need for more efficient production of recombinant proteins and biofuels has also driven the adoption of advanced mutagenesis techniques in industrial biotechnology. Additionally, regulatory support and government funding for genome-editing projects are further boosting market expansion, making cloning and mutagenesis an essential pillar of future scientific innovations.

SCOPE OF STUDY:

The report analyzes the Cloning and Mutagenesis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cloning Kits, Mutagenesis Kits, Other Product Types); Technology (Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology, Other Technologies); End-Use (Biopharmaceutical and Pharmaceutical Companies End-Use, CROs and CMOs End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Agilent Technologies, Inc.
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • Bolder BioTechnology, Inc.
  • Creative Biogene
  • Danaher Corporation
  • Genes2Me
  • Genewiz (Azenta Life Sciences)
  • Genomax Technologies Pte Ltd
  • GenScript
  • Integrated DNA Technologies (IDT)
  • Jena Bioscience GmbH
  • Merck KGaA
  • New England Biolabs
  • OriGene Technologies
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TransGen Biotech Co., Ltd.
  • Vazyme

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cloning and Mutagenesis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Applications of Functional Genomics and Protein Engineering Propel Growth of Cloning and Mutagenesis Tools
    • Expanding Biopharmaceutical R&D Activity Drives Demand for High-Fidelity Gene Cloning and Mutagenesis Technologies
    • Advancements in Site-Directed Mutagenesis Enhance Efficiency of Precision Genetic Modifications
    • Growing Use of Recombinant DNA Technologies in Synthetic Biology Expands Adoption of Cloning Techniques
    • Increased Demand for Custom Gene Synthesis and Expression Cloning Generates Market Opportunities
    • Rapid Progress in CRISPR and Genome Editing Research Spurs Adoption of Mutagenesis Protocols
    • Integration of Automation and High-Throughput Screening Enhances Workflow Efficiency in Cloning and Mutagenesis Labs
    • Expansion of Academic and Research Institutions Globally Strengthens Demand for Gene Manipulation Kits
    • Rising Focus on Protein Structure-Function Studies Propels Market for Directed Evolution and Mutagenesis
    • Growing Biotech Startup Activity Accelerates Commercial Use of Cloning Vectors and Mutation Libraries
    • Increased Application of Mutagenesis in Vaccine Development Drives Market Growth
    • Adoption of Mutagenesis Techniques for Enzyme Optimization and Industrial Biocatalysts Expands Use Cases
    • Rising Investments in Agricultural Biotechnology Fuel Demand for Plant Gene Cloning and Trait Improvement
    • Growing Trend Toward Personalized Medicine Supports Custom Gene Editing and Cloning Solutions
    • Availability of Cloud-Based Bioinformatics Tools Enhances Adoption of Cloning and Mutagenesis Protocols
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cloning and Mutagenesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cloning Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cloning Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Mutagenesis Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Mutagenesis Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Topo PCR Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Topo PCR Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Site-directed Mutagenesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Site-directed Mutagenesis Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Blunt End Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Blunt End Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Seamless Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Seamless Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION